|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Oral immune regulation using colitis extracted proteins for treatment of Crohn's disease: Results of a phase Ⅰ clinical trial显示文摘AIM: To evaluate safety and possible efficacy of induction of oral immune regulation using colitis extracted proteins(CEP) in Crohn's disease (CD) subjects.METHODS: Ten CDs were treated orally with autologous CEP thrice weekly for 16 wk. Subjects were monitored for CDAI and IBDQ. Immune modulatory effect was assessed by T-lymphocyte FACS analysis, CEP-specific IFNγ ELISPOT assay and cytokine levels.RESULTS: Induction of oral immune regulation significantly ameliorated disease activity. All (10/10) subjects had clinical response (CDAI≤70) and 7/10 achieved clinical remission (CDAI≤150). Significant increase in mean IBDQ score was noted (134±9vs 164±12). No treatment-related adverse events were noted. High levels of CEP-specific IFNγ spot forming colonies were detected in five subjects prior to treatment and in all five, a marked decrease was observed. The CD4+/CDS+ lymphocyte ratio and peripheral NKT cell numbers increased significantly, in 7/10 and in 5/10 subjects, respectively. Significant increase in serum IL-10 and IL-4 levels was observed in 7/10 subjects during treatment period.CONCLUSION: Immune regulation via oral administration of CEP is a safe and possibly effective treatment for subjects with moderate CD and may provide means of antigen-specific immune modulation. | Eran Israeli Eran Goldin Oren Shibolet Athalia Klein Nilla Hemed Dean Engelhardt Elazar Rabbani Yaron Ilan | 2005 | World Journal of Gastroenterology2005，11，20： | 8 |
| 2 | Preoperative imaging in staghorn calculi, planning and decision making in management of staghorn calculi显示文摘Objective:Staghorn calculi present a particular and challenging entity of stone morphology.Treatment is associated with lower stone-free rates and higher complication rates compared to non-staghorn stones.In this review we looked for the most relevant data on preoperative imaging and access planning to help decision making for percutaneous surgery with this complex condition.Methods:We conducted a PubMed search of publications in the past 2 decades that include relevant information on the planning for management of staghorn stones.Non-contrast computerized tomography(NCCT)is indeed the standard imaging tool for percutaneous nephrolithotomy(PCNL);additional tools such as three-dimensional computed tomography(CT)reconstruction of the staghorn calculus may help plan access in complex cases.Ultrasound guided percutaneous access may be considered for staghorn stones when planning upper pole access in kidney malposition or complex intrarenal anatomy or with complex body habitus.Wideband doppler ultrasound and real-time virtual sonography can assist.New technologies to improve kidney access such as Uro Dyna-CT or electromagnetic sensor have been reported,but have not shown utilization in staghorn cases.Staghorn morphometry-based prediction algorithms may predict the number of tract(s)and stage(s)for PCNL monotherapy.Lower pole access can be equally effective as upper pole when planning for staghorn and complex stones,with significantly less complications rate;Stone-Tract length-Obstruction-Number of involved calyces-Essence of stone density(STONE)nephrolithometry seems to be the best system to predict outcomes of PCNL in staghorn cases.There is a growing trend of endoscopic combined intrarenal surgery(ECIRS)in concordance with PCNL to treat larger stones.Conservative management of staghorn calculi is an undesired option,but can be an alternative for a carefully selected group of high-risk patients.Conclusion:Staghorn stones may lead to deterioration of renal function and life-threatening urosepsis.This entity should be managed aggressively with planning ahead for surgery using the different tools available as the cornerstone for a successful outcome. | Ilan Klein Jorge Gutierrez-Aceves | 2020 | Asian Journal of Urology2020，7，2： | 7 |
| 3 | Oral mixture of autologous colon-extracted proteins for the Crohn's disease: A double-blind trial显示文摘AIM: To evaluate the safety and efficacy of oral administration of AlequelTM, an autologous proteincontaining colon extract.a randomized,placebo-controlled,double-blind trial.Patients were orally administered with autologous protein-containing colon extract three doses of autologous study drug per week for 15 wk,for a total of45 doses.Patients were followed for safety parameters.Remission was defined as a Crohn’s disease activity index(CDAI)score of less than or equal to 150.All patients were followed for changes in subsets of T cells by fluorescence-activated cell sorting analysis.RESULTS:Analysis was performed on a total number of evaluable patients of 14 in the study drug group and15 in the placebo group.Treatment was well tolerated by all patients.No major treatment-related adverse events were reported or observed in any of the treated patients during the feeding or follow-up periods.Between weeks 6 and 9 of the study,six of the 14(43%)evaluable subjects who received the study drug achieved a CDAI of 150 or lower.In contrast,five of the 15(33%)evaluable subjects in the placebo group achieved remission.Between weeks 9 and 12,the remission rates were 50%and 33%for the drug group and placebo group,respectively.Among the drug-treated subjects who achieved remission,the effect of the drug was judged as stable in eight of the 14 subjects as measured by at least two CDAI scores indicating remission in the 15-wk treatment period.A decreased percentage of peripheral natural killer T regulatory cells(a decrease of 28%vs an increase of 16%)and an increased ratio of CD4+/CD8+T lymphocytes(an increase of 11%vs a decrease of9%)were noted in subjects with a significant clinical response.CONCLUSION:Oral administration of the autologous colonic extract could be a safe and effective for the treatment of patients with moderate to severe Crohn’s disease. | Eran Israeli Ehud Zigmond Gadi Lalazar Athalia Klein Nilla Hemed Eran Goldin Yaron Ilan | 2015 | World Journal of Gastroenterology2015，21，18： | 3 |
| 4 | Reverse Remodeling and the Risk of Ventricular Tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy)显示文摘 | Alon Barsheshet Paul J. Wang Arthur J. Moss Scott D. Solomon Amin Al-Ahmad Scott McNitt Elyse Foster David T. Huang Helmut U. Klein Wojciech Zareba Michael Eldar Ilan Goldenberg | 2011 | Journal of the American College of Cardiology2011，，24： | 1 |
| 5 | Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT-CRT)显示文摘 | Wojciech Zareba Helmut Klein Iwona Cygankiewicz W. Jackson Hall Scott McNitt Mary Brown David Cannom James P. Daubert Michael Eldar Michael R. Gold Jeffrey J. Goldberger Ilan Goldenberg Edgar Lichstein Heinz Pitschner Mayer Rashtian Scott Solomon Sami Vis | 2011 | Circulation2011，，： | 1 |
| 6 | Left Ventricular Lead Position and Clinical Outcome in the Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT-CRT) Trial显示文摘 | Jagmeet P. Singh Helmut U. Klein David T. Huang Sven Reek Malte Kuniss Aurelio Quesada Alon Barsheshet David Cannom Ilan Goldenberg Scott McNitt James P. Daubert Wojciech Zareba Arthur J. Moss | 2011 | Circulation2011，，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员